{"id":"vinorelbin","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Bone marrow depression","Breastfeeding (mother)","Disorder of lung","Gastrointestinal obstruction","Gastrointestinal perforation","Hepatic Metastases","Hepatic failure","Infectious disease","Interstitial pneumonia","Intestinal Ischemic Necrosis","Intestinal obstruction","Leukopenia","Pregnancy, function","Severe Granulocytopenia"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00006088","NCT00325234","NCT00003963","NCT00683514","NCT00312819","NCT01664663","NCT02919462","NCT06072612","NCT00011414","NCT00670982","NCT01271725","NCT00642824","NCT00496275","NCT05238831","NCT02144194","NCT05553782","NCT01520103","NCT01007942","NCT01565083","NCT03986463","NCT00030459","NCT01835236","NCT02299999","NCT04400695","NCT05594095","NCT07420439","NCT05487391","NCT02083211","NCT01185509","NCT03006614","NCT01687439","NCT01441752","NCT00958724","NCT04745975","NCT00426530","NCT00906698","NCT05999994","NCT00706069","NCT06533722","NCT01216527","NCT00309972","NCT00432562","NCT00912275","NCT05856383","NCT00686959","NCT00215462","NCT06211881","NCT01060514","NCT06383767","NCT02985658"],"aliases":["Navelbine"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Vinorelbin","companyId":"national-cancer-institute-slovakia","ecosystem":[],"mechanism":{"target":"Substance-K receptor, Cytochrome P450 3A4, Tubulin beta","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"National Cancer Institute, Slovakia","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Vinorelbin","indications":{"approved":[{"name":"Non-small cell lung cancer","diseaseId":"non-small-cell-lung-cancer","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00006088","phase":"Phase 1","title":"A Phase I Absolute Bioavailability Study of Oral NAVELBINE (Vinorelbine Tartrate) in Patients With Solid Tumors","status":"UNKNOWN","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","isPivotal":false,"enrollment":0,"indication":"Unspecified Adult Solid Tumor, Protocol Specific","completionDate":""},{"nctId":"NCT00325234","phase":"Phase 2","title":"A Randomized Phase II Study of Two Chemotherapy Regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxanes Pretreated Advanced Breast Cancer Patients","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":135,"indication":"Breast Cancer","completionDate":"2010-08"},{"nctId":"NCT00003963","phase":"Phase 2","title":"Treatment of B-Cell NHL Relapsing After Transplant With a Rituxan Vinorelbine Combination","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","isPivotal":false,"enrollment":14,"indication":"Lymphoma","completionDate":"2005-02"},{"nctId":"NCT00683514","phase":"Phase 3","title":"Oral Vinorelbine And Cisplatin With Concomitant Radiotherapy Followed By Either Consolidation Therapy With Oral Vinorelbine And Cisplatin Plus Best Supportive Care Or Best Supportive Care Alone In Sta","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","isPivotal":true,"enrollment":201,"indication":"NSCLC","completionDate":""},{"nctId":"NCT00312819","phase":"Phase 2","title":"Randomized Phase 2 Trial of Treatment of Advanced Non Small Cell Lung Carcinoma With/Without Disulfiram and Cisplatin Navelbine","status":"COMPLETED","sponsor":"Hadassah Medical Organization","isPivotal":true,"enrollment":60,"indication":"Non-small Cell Lung Cancer","completionDate":"2009-12"},{"nctId":"NCT01664663","phase":"Phase 2","title":"Phase II Randomized Study on Locally Advanced Non Small Cell Lung Cancer Escalated Dose on Individual Basis Treatment With Radiochemotherapy","status":"TERMINATED","sponsor":"Ass. Prof. Jan Nyman","isPivotal":false,"enrollment":37,"indication":"Non Small Cell Lung Cancer, Locally Advanced Disease","completionDate":"2015-10"},{"nctId":"NCT02919462","phase":"Phase 2","title":"Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous No","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","isPivotal":false,"enrollment":2,"indication":"Carcinoma, Non-Small-Cell Lung, Secondary","completionDate":"2017-05"},{"nctId":"NCT06072612","phase":"Phase 3","title":"Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","isPivotal":true,"enrollment":404,"indication":"Breast Cancer, Metastatic Breast Cancer","completionDate":"2028-06"},{"nctId":"NCT00011414","phase":"Phase 1","title":"Phase I Trial and Pharmacokinetic Study of Tariquidar (XR9576), a P-Glycoprotein Inhibitor, in Combination With Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients With Refractory Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":29,"indication":"Wilms' Tumor, Sarcoma","completionDate":"2016-01-13"},{"nctId":"NCT00670982","phase":"Phase 2","title":"Phase 2 Study of Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Harold J. Burstein, MD, PhD","isPivotal":false,"enrollment":29,"indication":"Breast Cancer","completionDate":"2012-12"},{"nctId":"NCT01271725","phase":"Phase 2","title":"LUX-Breast 2; An Open Label, Phase II Trial of Afatinib (BIBW 2992) in Patients With Metastatic HER2-overexpressing Breast Cancer Failing HER2-targeted Treatment in the Neoadjuvant and/or Adjuvant Tre","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":74,"indication":"Breast Neoplasms","completionDate":"2017-03-13"},{"nctId":"NCT00642824","phase":"Phase 2","title":"Local Substudy Associated to the International Study MO19390 to Determine the BRCA1 Gene mRNA Expression as a Predictive Marker of Response to Chemotherapy","status":"TERMINATED","sponsor":"Hoffmann-La Roche","isPivotal":false,"enrollment":3,"indication":"Non-Squamous Non-Small Cell Lung Cancer","completionDate":"2009-12"},{"nctId":"NCT00496275","phase":"Phase 1","title":"A Phase I, Open Label Study to Assess the Safety and Tolerability of ZD6474 (ZACTIMA) in Combination With Vinorelbine (Navelbine) or Gemcitabine (Gemzar) Plus Cisplatin as First Line Therapy in Patien","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":17,"indication":"Non Small Cell Lung Cancer","completionDate":"2007-05"},{"nctId":"NCT05238831","phase":"EARLY/Phase 1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","isPivotal":false,"enrollment":0,"indication":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm","completionDate":"2026-05-31"},{"nctId":"NCT02144194","phase":"Phase 2","title":"TNM Trial: Upfront Docetaxel [T] and Alternating iv and Oral Vinorelbine [N] Followed, by Either Maintenance Oral Vinorelbine, or Observation for Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Cancer Research Group - Collaborative Group, Beirut, Lebanon.","isPivotal":false,"enrollment":65,"indication":"Breast Cancer","completionDate":"2017-12"},{"nctId":"NCT05553782","phase":"EARLY/Phase 1","title":"Therapeutic Drug Screening Using a Novel Implantable Microdevice (IMD) in Head and Neck Cancers: a Window of Opportunity Study","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","isPivotal":false,"enrollment":30,"indication":"Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland","completionDate":"2029-08-01"},{"nctId":"NCT01520103","phase":"Phase 2","title":"Randomized Phase II Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","isPivotal":false,"enrollment":139,"indication":"Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer","completionDate":"2016-10-31"},{"nctId":"NCT01007942","phase":"Phase 3","title":"A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locall","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":true,"enrollment":569,"indication":"HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer","completionDate":"2015-06"},{"nctId":"NCT01565083","phase":"Phase 2","title":"A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Adv","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":false,"enrollment":213,"indication":"Breast Cancer","completionDate":"2015-10"},{"nctId":"NCT03986463","phase":"N/A","title":"CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","isPivotal":false,"enrollment":40,"indication":"Lung Neoplasms, Lung Cancer","completionDate":"2020-12-31"},{"nctId":"NCT00030459","phase":"Phase 2","title":"Randomized Feasibility Study Of Active Symptom Control With Or Without Chemotherapy In The Treatment Of Patients With Mesothelioma","status":"UNKNOWN","sponsor":"British Thoracic Society","isPivotal":false,"enrollment":0,"indication":"Malignant Mesothelioma","completionDate":""},{"nctId":"NCT01835236","phase":"Phase 2","title":"A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast ","status":"COMPLETED","sponsor":"Swiss Cancer Institute","isPivotal":false,"enrollment":208,"indication":"Metastatic Breast Cancer","completionDate":"2020-05-26"},{"nctId":"NCT02299999","phase":"Phase 2","title":"PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cance","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","isPivotal":false,"enrollment":1460,"indication":"Metastatic Breast Cancer","completionDate":"2025-12"},{"nctId":"NCT04400695","phase":"Phase 3","title":"Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","isPivotal":true,"enrollment":366,"indication":"Breast Cancer","completionDate":"2024-12-30"},{"nctId":"NCT05594095","phase":"Phase 2","title":"Precision Platform Study of HR+/ HER2-advanced Breast Cancer Based on SNF Typing (A Prospective, Open-label, Multi-center, Phase II Platform Study)","status":"RECRUITING","sponsor":"Fudan University","isPivotal":false,"enrollment":620,"indication":"Breast Neoplasm, Breast Cancer","completionDate":"2026-12-01"},{"nctId":"NCT07420439","phase":"Phase 2","title":"Phase II Trial Assessing 1st Line and 2nd Line Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","isPivotal":false,"enrollment":108,"indication":"Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD)","completionDate":"2028-11-15"},{"nctId":"NCT05487391","phase":"Phase 3","title":"QL1706 Combined With Platinum-based Chemotherapy Versus Placebo Combined With Platinum-based Chemotherapy as Adjuvant Therapy for Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resec","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","isPivotal":true,"enrollment":632,"indication":"Carcinoma, Non-Small-Cell Lung","completionDate":"2029-05-22"},{"nctId":"NCT02083211","phase":"Phase 3","title":"Phase III Clinical Trial: \"Evaluation of the Combination of Nimotuzumab and Cisplatin-Vinorelbine in First Line Chemotherapy in the Survival of Patients With Recurring-Persistent Cervical Carcinoma\"","status":"COMPLETED","sponsor":"National Institute of Cancerología","isPivotal":true,"enrollment":168,"indication":"Cervical Cancer Recurrent or Persistent, Palliative Treatment","completionDate":"2014-06"},{"nctId":"NCT01185509","phase":"Phase 2","title":"A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With Human Epidermal Growth Factor-2 (HER2) Negative Prim","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","isPivotal":false,"enrollment":31,"indication":"Breast Cancer, Metastatic Breast Cancer","completionDate":"2018-01"},{"nctId":"NCT03006614","phase":"Phase 3","title":"Using PERS(PErsonalized Regimen Selection) Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer Multicentric, Prospective, Randomized Controlled Phase III Clini","status":"UNKNOWN","sponsor":"Shi Yanxia","isPivotal":true,"enrollment":320,"indication":"Breast Cancer Model, Effects of Chemotherapy","completionDate":"2023-03"},{"nctId":"NCT01687439","phase":"Phase 2","title":"Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Fudan University","isPivotal":false,"enrollment":15,"indication":"Non-small Cell Lung Cancer","completionDate":"2009-10"},{"nctId":"NCT01441752","phase":"Phase 3","title":"State Administration of Traditional Chinese Medicine of Shanghai","status":"COMPLETED","sponsor":"xuling","isPivotal":true,"enrollment":349,"indication":"Non-small Cell Lung Cancer","completionDate":"2015-03"},{"nctId":"NCT00958724","phase":"Phase 1","title":"A Phase 1 Study Of Neratinib (HKI-272) In Combination With Vinorelbine In Japanese Subjects With Advanced Or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Puma Biotechnology, Inc.","isPivotal":false,"enrollment":6,"indication":"Advanced Malignant Solid Tumors","completionDate":"2010-04"},{"nctId":"NCT04745975","phase":"Phase 2","title":"GUided Treatment Based on Mini-PDX in metastaTIc refractOry Triple Negative Breast Cancer(GUMPTION)：a Prospective Randomized Controlled Single Center Clinical Trial","status":"UNKNOWN","sponsor":"Fudan University","isPivotal":false,"enrollment":100,"indication":"Triple Negative Breast Cancer","completionDate":"2023-01"},{"nctId":"NCT00426530","phase":"Phase 1","title":"A Phase Ib Study Investigating the Combination of Everolimus With Trastuzumab and Vinorelbine in Patients With HER2-overexpressing Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":50,"indication":"Breast Neoplasms, Neoplasm Metastasis","completionDate":"2010-06"},{"nctId":"NCT00906698","phase":"Phase 1","title":"Phase I Open Label Trial to Assess Safety of BIBW 2992 With Vinorelbine in Solid Tumors Known to Overexpress HER2 and/or EGFR","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":55,"indication":"Neoplasms","completionDate":"2013-01"},{"nctId":"NCT05999994","phase":"Phase 2","title":"CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research","status":"RECRUITING","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":105,"indication":"Neoplasms, Child","completionDate":"2027-05"},{"nctId":"NCT00706069","phase":"Phase 1","title":"A Phase I Study Of Vinorelbine Oral Plus Capecitabine Combination In Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","isPivotal":false,"enrollment":40,"indication":"Metastatic Breast Cancer","completionDate":"2009-07"},{"nctId":"NCT06533722","phase":"Phase 2","title":"A Phase II Study of the Efficacy and Safety of Adaptive Therapy for Metastatic Refractory Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","isPivotal":false,"enrollment":10,"indication":"HER2-negative Metastatic Breast Cancer","completionDate":"2025-05-28"},{"nctId":"NCT01216527","phase":"Phase 3","title":"A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery Versus Surgery for Locally Advanced Squamous Cell Esophageal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","isPivotal":true,"enrollment":430,"indication":"Squamous Cell Esophageal Carcinoma","completionDate":"2019-12"},{"nctId":"NCT00309972","phase":"Phase 3","title":"A Randomized Phase III Trial of Sequential Chemotherapy Followed By Radical Radiotherapy Versus Concurrent Chemo-Radiotherapy Followed by Chemotherapy in Patients With Inoperable Stage III Non-Small C","status":"COMPLETED","sponsor":"University College, London","isPivotal":true,"enrollment":130,"indication":"Lung Cancer","completionDate":"2012-02"},{"nctId":"NCT00432562","phase":"Phase 1","title":"A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion (ANX-530) in Patients With Advanced Cancer.","status":"COMPLETED","sponsor":"Mast Therapeutics, Inc.","isPivotal":false,"enrollment":31,"indication":"Breast Cancer, Non-small Cell Lung Cancer","completionDate":"2007-12"},{"nctId":"NCT00912275","phase":"Phase 1","title":"Phase I/II Study of Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Taiwan University Hospital","isPivotal":false,"enrollment":46,"indication":"Metastatic Breast Cancer","completionDate":"2017-07-07"},{"nctId":"NCT05856383","phase":"N/A","title":"Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in the Treatment of Advanced Breast Cancer","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","isPivotal":false,"enrollment":100,"indication":"HER2-positive Advanced Breast Cancer","completionDate":"2027-12-31"},{"nctId":"NCT00686959","phase":"Phase 3","title":"Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice i","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":true,"enrollment":598,"indication":"Non Small Cell Lung Cancer","completionDate":"2014-11"},{"nctId":"NCT00215462","phase":"Phase 2","title":"A Phase II Study of Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","isPivotal":false,"enrollment":32,"indication":"Esophageal Cancer, Gastric Cancer","completionDate":"2005-08"},{"nctId":"NCT06211881","phase":"NA","title":"Chidamide Combined With Gemcitabine, Vinorelbine, and Mitoxantrone Hydrochloride Liposome (Chi-GVM) Regimen for the Treatment of Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL) :A Multicen","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","isPivotal":false,"enrollment":50,"indication":"Relapsed/Refractory Peripheral T-cell Lymphoma","completionDate":"2025-09-30"},{"nctId":"NCT01060514","phase":"Phase 1","title":"Phase I Study of Pazopanib in Combination With Vinorelbine in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer","status":"TERMINATED","sponsor":"Northwestern University","isPivotal":false,"enrollment":8,"indication":"Metastatic Non Small Cell Lung Cancer, Metastatic Breast Cancer","completionDate":"2013-09"},{"nctId":"NCT06383767","phase":"Phase 3","title":"A Open-label, Randomized, Multicenter Phase III Study of ESG401 Versus Investigator's Choice Chemotherapy in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Leas","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","isPivotal":true,"enrollment":378,"indication":"Metastatic Breast Cancer","completionDate":"2028-07-31"},{"nctId":"NCT02985658","phase":"N/A","title":"Expanded Access Protocol With ABT-888 (Veliparib) in Patients With Metastatic BRCA-Mutation Associated or Triple Negative Breast Cancer","status":"NO_LONGER_AVAILABLE","sponsor":"University of Washington","isPivotal":false,"enrollment":0,"indication":"Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer","completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}